bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Here’s Why

bioMerieux (OTCMKTS:BMXMF)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $87.42, but opened at $83.31. bioMerieux shares last traded at $83.31, with a volume of 10 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of bioMerieux from a “buy” rating to a “hold” rating in a research report on Friday, April 24th. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat, bioMerieux presently has a consensus rating of “Hold”.

bioMerieux Stock Performance

The business’s 50-day moving average is $95.78 and its two-hundred day moving average is $112.60. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.